Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Isotretinoin + Naxitamab + Sargramostim |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Isotretinoin | Accutane Roche | Not Available | ||
| Naxitamab | Danyelza | hu3F8 | GD2 Antibody 6 | Danyelza (naxitamab) is an antibody that targets the ganglioside GD2, potentially resulting in increased anti-tumor immune response against GD2-expressing tumor cells (PMID: 22754766). Danyelza (naxitamab) is FDA approved for use in combination with GM-CSF in pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who achieved a partial response, minor response, or stable disease to prior therapy (FDA.gov). |
| Sargramostim | Leukine | GM-CSF|Prokine |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03033303 | Phase II | Isotretinoin + Naxitamab + Sargramostim | A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma | Completed | USA | 0 |